Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary

American Journal of Obstetrics and Gynecology

Volumn 198, Issue 4, 2008, Pages 418.e1-418.e7

  Ødegaard, Elin ^a   Davidson, Ben ^b   Elgaaen, Bente Vilming ^a   Fagerhol, Magne K ^a,c   Engh, Vibeke ^a   Onsrud, Mathias ^a,c   Staff, Anne Cathrine ^a,c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

calprotectin; inflammation; ovarian cancer; ovarian neoplasm

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CALGRANULIN; EDETIC ACID;

ARTICLE; BENIGN TUMOR; BLOOD SAMPLING; CANCER INVASION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 41349086626     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2007.10.792     Document Type: Article

References (26)

1. Jemal A., Tiwari R.C., Murray T., et al. Cancer statistics, 2004. CA Cancer J Clin 54 (2004) 8-29
2. Winter III W.E., Kucera P.R., Rodgers W., McBroom J.W., Olsen C., and Maxwell G.L. Surgical staging in patients with ovarian tumors of low malignant potential. Obstet Gynecol 100 (2002) 671-676
3. Shih I., and Kurman R.J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164 (2004) 1511-1518
4. Fagerhol M.K. Nomenclature for proteins: is calprotectin a proper name for the elusive myelomonocytic protein?. Clin Mol Pathol 49 (1996) M74-M79
5. Fagerhol M.K., Dale I., and Andersson T. Release and quantitation of a leucocyte derived protein (L1). Scand J Haematol 24 (1980) 393-398
6. Odink K., Cerletti N., Bruggen J., et al. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature 330 (1987) 80-82
7. Hermani A., Hess J., De Servi B., et al. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res 11 (2005) 5146-5152
8. Gebhardt C., Nemeth J., Angel P., and Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 72 (2006) 1622-1631
9. Ott H.W., Lindner H., Sarg B., et al. Calgranulins in cystic fluid and serum from patients with ovarian carcinomas. Cancer Res 63 (2003) 7507-7514
10. Steinbakk M., Naess-Andresen C.F., Lingaas E., Dale I., Brandtzaeg P., and Fagerhol M.K. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 336 (1990) 763-765
11. Kocher M., Kenny P.A., Farram E., Abdul Majid K.B., Finlay-Jones J.J., and Geczy C.L. Functional chemotactic factor CP-10 and MRP-14 are abundant in murine abscesses. Infect Immun 64 (1996) 1342-1350
12. Fagerhol M.K. Calprotectin, a faecal marker of organic gastrointestinal abnormality. Lancet 356 (2000) 1783-1784
13. Murao S., Collart F.R., and Huberman E. A protein containing the cystic fibrosis antigen is an inhibitor of protein kinases. J Biol Chem 264 (1989) 8356-8360
14. Yui S., Nakatani Y., and Mikami M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol Pharm Bull 26 (2003) 753-760
15. Nagase H., and Woessner Jr. J.F. Matrix metalloproteinases. J Biol Chem 274 (1999) 21491-21494
16. El-Rifai W., Moskaluk C.A., Abdrabbo M.K., et al. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 62 (2002) 6823-6826
17. Arai K., Yamada T., and Nozawa R. Immunohistochemical investigation of migration inhibitory factor-related protein (MRP)-14 expression in hepatocellular carcinoma. Med Oncol 17 (2000) 183-188
18. Arai K., Teratani T., Kuruto-Niwa R., Yamada T., and Nozawa R. S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. Eur J Cancer 40 (2004) 1179-1187
19. Dale I., and Brandtzaeg P. Expression of the epithelial L1 antigen as an immunohistochemical marker of squamous cell carcinoma of the lung. Histopathology 14 (1989) 493-502
20. Kristinsson J., Roseth A., Fagerhol M.K., et al. Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum 41 (1998) 316-321
21. Tingulstad S., Hagen B., Skjeldestad F.E., Halvorsen T., Nustad K., and Onsrud M. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol 93 (1999) 448-452
22. Trope C., and Kaern J. Management of borderline tumors of the ovary: state of the art. Semin Oncol 25 (1998) 372-380
23. Terry K.L., Sluss P.M., Skates S.J., et al. Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers 20 (2004) 53-70
24. Yurkovetsky Z.R., Linkov F.Y., Malehorn E., and Lokshin A.E. Multiple biomarker panels for early detection of ovarian cancer. Future Oncol 2 (2006) 733-741
25. Ye B., Gagnon A., and Mok S.C. Recent technical strategies to identify diagnostic biomarkers for ovarian cancer. Expert Rev Proteomics 4 (2007) 121-131
26. Agarwal R., Whang D.H., Alvero A.B., et al. Macrophage migration inhibitory factor expression in ovarian cancer. Am J Obstet Gynecol 196 (2007) 348-355